Comp Immunol Microbiol Infect Dis 2007 Sep 3;30(5-6):391-8. Epub 2007 Jul 3.
Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan.
Download full-text PDF
J Med Microbiol 2012 Jan 18;61(Pt 1):8-15. Epub 2011 Aug 18.
Defence Science and Technology Laboratories (Dstl), Porton Down, Salisbury, Wiltshire, UK.
Normal immunocompetent mice are not susceptible to non-adapted filoviruses. There are therefore two strategies available to establish a murine model of filovirus infection: adaptation of the virus to the host or the use of genetically modified mice that are susceptible to the virus. A number of knockout (KO) strains of mice with defects in either their adaptive or innate immunity are susceptible to non-adapted filoviruses. Read More
J Virol 2006 Mar;80(6):2738-46
Division of Biodefense Vaccines, GenPhar, Inc., 871 Lowcountry Blvd., Mount Pleasant, South Carolina 29464, USA.
Ebola virus (EBOV) causes a severe hemorrhagic fever for which there are currently no vaccines or effective treatments. While lethal human outbreaks have so far been restricted to sub-Saharan Africa, the potential exploitation of EBOV as a biological weapon cannot be ignored. Two species of EBOV, Sudan ebolavirus (SEBOV) and Zaire ebolavirus (ZEBOV), have been responsible for all of the deadly human outbreaks resulting from this virus. Read More
Biochem Biophys Res Commun 2011 Apr 6;407(1):74-8. Epub 2011 Mar 6.
Laboratory of Cancer Biology and Molecular Immunology, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo 113-0033, Japan.
Ebola virus (EBOV) infection is initiated by the interaction of the viral surface envelope glycoprotein (GP) with the binding sites on target cells. Differences in the mortality among different species of the Ebola viruses, i.e. Read More
J Virol 2009 Jul 22;83(14):7296-304. Epub 2009 Apr 22.
Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
The filoviruses Marburg virus and Ebola virus cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (VSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Here, we performed a proof-of-concept study in order to determine the potential of having one single-injection vaccine capable of protecting nonhuman primates against Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Cote d'Ivoire ebolavirus (CIEBOV), and Marburgvirus (MARV). Read More